Sane R, Wu SP, Zhang R, Gallo JM.
The effect of ABCG2 and ABCC4 on the pharmacokinetics of methotrexate in the brain.
Drug Metabolism and Disposition: the Biological Fate of Chemicals 2014 Apr; 42(4).
Ballesta A, Zhou Q, Zhang X, Lv H, Gallo JM.
Multiscale design of cell-type-specific pharmacokinetic/pharmacodynamic models for personalized medicine: application to temozolomide in brain tumors.
CPT: Pharmacometrics & Systems Pharmacology 2014; 3.
Zhang XY, Birtwistle MR, Gallo JM.
A general network pharmacodynamic model-based design pipeline for customized cancer therapy applied to the VEGFR pathway.
CPT: Pharmacometrics & Systems Pharmacology. 2014 Jan 15;3:e92. doi: 10.1038/psp.2013.65.
Birtwistle MR, Mager DE, Gallo JM.
Mechanistic vs. empirical network models of drug action.
CPT: Pharmacometrics & Systems Pharmacology. 2013 Sep 6;2:e72. doi: 10.1038/psp.2013.51.
Sharma J, Lv H, Gallo JM.
Intratumoral modeling of gefitinib pharmacokinetics and pharmacodynamics in an orthotopic mouse model of glioblastoma.
Cancer Research. 2013 Aug 15;73(16):5242-52.
Tiwari AK, Zhang R, Gallo JM.
Overlapping functions of ABC transporters in topotecan disposition as determined in gene knockout mouse models.
Molecular Cancer Therapeutics. 2013 Jul;12(7):1343-55.
Gallo JM.
Physiologically based pharmacokinetic models of tyrosine kinase inhibitors: a systems pharmacological approach to drug disposition.
Clinical Pharmacology & Therapeutics. 2013 Mar;93(3):236-8. doi: 10.1038/clpt.2012.244. Epub 2012 Dec 18.
Lv H, Zhang X, Sharma J, Reddy MV, Reddy EP, Gallo JM.
Integrated pharmacokinetic-driven approach to screen candidate anticancer drugs for brain tumor chemotherapy.
AAPS Journal. 2013 Jan;15(1):250-7. doi: 10.1208/s12248-012-9428-4. Epub 2012 Nov 22.
Lv H, Wang F, Reddy MV, Zhou Q, Zhang X, Reddy EP, Gallo JM.
Screening candidate anticancer drugs for brain tumor chemotherapy: Pharmacokinetic-driven approach for a series of (E)-N-(substituted aryl)-3-(substituted phenyl)propenamide analogues.
Investigational New Drugs. 2012 Dec;30(6):2263-73. doi: 10.1007/s10637-012-9806-x. Epub 2012 Mar 1.
Zhou Q, Lv H, Mazloom AR, Xu H, Ma’ayan A, Gallo JM.
Activation of Alternate Pro-Survival Pathways Accounts for Acquired Sunitinib Resistance in U87MG Glioma Xenografts.
Journal of Pharmacology and Experimental Therapeutics. 2012 Nov;343(2):509-19. doi: 10.1124/jpet.112.196097. Epub 2012 Aug 6.
Sharma J, Lv H, Gallo JM.
Analytical approach to characterize the intratumoral pharmacokinetics and pharmacodynamics of gefitinib in a glioblastoma model.
Journal of Pharmaceutical Sciences. 2012 Nov;101(11):4100-6. doi: 10.1002/jps.23283. Epub 2012 Aug 1.
Iyengar R, Zhao S, Chung SW, Mager DE, Gallo JM.
Merging systems biology with pharmacodynamics.
Science Translational Medicine. 2012 Mar 21;4(126):126ps7.
Nuthalapati S, Guo P, Zhou Q, Reddy MV, Reddy EP, Gallo JM.
Application of a liquid chromatography-tandem mass spectrometry (LC/MS/MS) method to the pharmacokinetics of ON01910 in brain tumor-bearing mice.
Journal of Pharmaceutical and Biomedical Analysis. 2011 Dec 15;56(5):1117-20.
Wang Z, Zhou Q, Kruh GD, Gallo JM.
Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models.
Drug Metabolism and Disposition. 2011 Nov;39(11):2155-61.
Zhou Q, Gallo JM.
The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic.
AAPS Journal. 2011 Mar;13(1):111-20.
Denora N, Laquintana V, Trapani A, Lopedota A, Latrofa A, Gallo JM, Trapani G.
Translocator protein (TSPO) ligand-Ara-C (cytarabine) conjugates as a strategy to deliver antineoplastic drugs and to enhance drug clinical potential.
Molecular Pharmaceutics. 2010 Dec 6;7(6):2255-69.
Wang F, Zhou F, Kruh GD, Gallo JM.
Influence of blood-brain barrier efflux pumps on the distribution of vincristine in brain and brain tumors.
Neuro-Oncology. 2010 Oct;12(10):1043-9.
Gallo JM.
Pharmacokinetic/ pharmacodynamic-driven drug development.
Mt Sinai Journal of Medicine. 2010 Jul-Aug;77(4):381-8.
Zhou Q, Gallo JM.
Quantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography-electrospray ionization-tandem mass spectrometry and pharmacokinetic application.
Journal of Pharmaceutical and Biomedical Analysis. 2010 Mar 11;51(4):958-64.
Zhou Q, Gallo JM.
Differential effect of sunitinib on the distribution of temozolomide in an orthotopic brain tumor model.
Neuro-Oncology. 2009 Jun;11(3):301-10.
Wang S, Zhou Q, Gallo JM.
Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib.
Molecular Cancer Therapeutics. 2009 Jun;8(6):1438-47.
Rosso L, Brock CS, Gallo JM, Saleem A, Price PM, Turkheimer FE, Aboagye EO.
A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients.
Cancer Research. 2009 Jan 1;69(1):120-7.
Zhou Q, Guo P, Gallo JM.
Impact of antiangiogenesis inhibition by sunitinib on tumor distribution of temozolomide.
Clinical Cancer Research. 2008 Mar 1;14(5):1540-9.
Wang S, Guo P, Wang X, Zhou Q, Gallo JM.
Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models.
Molecular Cancer Therapeutics. 2008 Feb;7(2):407-17.
Zhou Q, Guo P, Kruh GD, Vicini P, Wang X, Gallo JM.
Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition.
Clin Cancer Res. 2007 Jul 15;13(14):4271-9.
Zhou Q, Guo P, Wang X, Nuthalapati S, Gallo JM.
Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens.
Journal of Pharmacology and Experimental Therapeutics. 2007 Apr;321(1):265-75.
Gallo JM, Vicini P, Orlansky A, Li S, Zhou F, Ma J, Pulfer S, Bookman MA, Guo P.
Pharmacokinetic model-predicted anticancer drug concentrations in human tumors.
Clinical Cancer Research. 2004 Dec 1;10(23):8048-58.
Gallo JM, Li S, Guo P, Reed K, Ma, J.
The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice.
Cancer Research. 2003 Aug 15;63(16):5114-7.
Ma J, Li S, Reed K, Guo P, Gallo JM.
Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide (TMZ) in subcutaneous and intracerebral human glioma xenograft models.
Journal of Pharmacology and Experimental Therapeutics. 2003 Jun;305(3):833-9.
Ma J, Reed K, Gallo JM.
Cells designed to deliver anticancer drugs by apoptosis.
Cancer Research. 2002 Mar 1;62(5):1382-7.
Ma J, Pulfer S, Li S, Chu J, Reed K, Gallo JM.
Pharmacodynamic mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP 470.
Cancer Research. 2001 Jul 15;61(14):5491-8.
Gallo JM, Laub PB, Rowinsky EK, Grochow LB, Baker SD.
Population pharmacokinetic model for topotecan derived from phase I clinical trials.
Journal of Clinical Oncology. 2000 Jun;18(12):2459-67.
Devineni D, Klein Szanto A, Gallo JM.
Uptake of temozolomide in a rat glioma model in the absence and presence of the angiogenesis inhibitor TNP 470.
Cancer Research. 1996 May 1;56(9):1983-7.
Gallo JM, Brennan J, Halbher T, Laub P, Ozols RF, O’Dwyer PJ.
Time dependent pharmacodynamic models in cancer chemotherapy: Population pharmacodynamic model for glutathione depletion following administration of buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO.
Cancer Research. 1995 Oct 15;55(20):4507-11.